Show simple item record

dc.contributor.authorSweeney, TEen_US
dc.contributor.authorPerumal, TMen_US
dc.contributor.authorHenao, Ren_US
dc.contributor.authorNichols, Men_US
dc.contributor.authorHowrylak, JAen_US
dc.contributor.authorChoi, AMen_US
dc.contributor.authorBermejo-Martin, JFen_US
dc.contributor.authorAlmansa, Ren_US
dc.contributor.authorTamayo, Een_US
dc.contributor.authorDavenport, EEen_US
dc.contributor.authorBurnham, KLen_US
dc.contributor.authorHinds, CJen_US
dc.contributor.authorKnight, JCen_US
dc.contributor.authorWoods, CWen_US
dc.contributor.authorKingsmore, SFen_US
dc.contributor.authorGinsburg, GSen_US
dc.contributor.authorWong, HRen_US
dc.contributor.authorParnell, GPen_US
dc.contributor.authorTang, Ben_US
dc.contributor.authorMoldawer, LLen_US
dc.contributor.authorMoore, FEen_US
dc.contributor.authorOmberg, Len_US
dc.contributor.authorKhatri, Pen_US
dc.contributor.authorTsalik, ELen_US
dc.contributor.authorMangravite, LMen_US
dc.contributor.authorLangley, RJen_US
dc.date.accessioned2019-07-23T13:05:29Z
dc.date.available2018-01-18en_US
dc.date.issued2018-02-15en_US
dc.identifier.urihttps://qmro.qmul.ac.uk/xmlui/handle/123456789/58622
dc.description.abstractImproved risk stratification and prognosis prediction in sepsis is a critical unmet need. Clinical severity scores and available assays such as blood lactate reflect global illness severity with suboptimal performance, and do not specifically reveal the underlying dysregulation of sepsis. Here, we present prognostic models for 30-day mortality generated independently by three scientific groups by using 12 discovery cohorts containing transcriptomic data collected from primarily community-onset sepsis patients. Predictive performance is validated in five cohorts of community-onset sepsis patients in which the models show summary AUROCs ranging from 0.765-0.89. Similar performance is observed in four cohorts of hospital-acquired sepsis. Combining the new gene-expression-based prognostic models with prior clinical severity scores leads to significant improvement in prediction of 30-day mortality as measured via AUROC and net reclassification improvement index These models provide an opportunity to develop molecular bedside tests that may improve risk stratification and mortality prediction in patients with sepsis.en_US
dc.description.sponsorshipy NIGMS Glue Grant Legacy Award R24GM102656. J.F.B.-M., R.A., and E.T. were supported by Instituto de Salud Carlos III (grants EMER07/050, PI13/02110, PI16/01156). R.J.L. was supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001417. The CAPSOD study was supported by NIH (U01AI066569, P20RR016480, HHSN266200400064C). P.K. is supported by grants from Bill Melinda Gates Foundation, R01 AI125197-01, 1U19AI109662, and U19AI057229, outside the submitted work. The GAinS study was supported by the National Institute for Health Research through the Comprehensive Clinical Research Network for patient recruitment; Wellcome Trust (Grants 074318 [to J.C.K.], and 090532/Z/09/Z [core facilities Wellcome Trust Centre for Human Genetics including High-Throughput Genomics Group]); European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013)/ERC Grant agreement no. 281824 (to J.C.K.), the Medical Research Council (98082 [to J.C.K.]); UK Intensive Care Society; and NIHR Oxford Biomedical Research Centre. The Duke HAI study was supported by a research agreement between Duke University and Novartis Vaccines and Diagnostics, Inc. According to the terms of the agreement, representatives of the sponsor had an opportunity to review and comment on a draft of the manuscript. The authors had full control of the analyses, the preparation of the manuscript, and the decision to submit the manuscript for publication. For the University of Florida ‘P50’ Study, data were obtained from the Sepsis and Critically Illness Research Center (SCIRC) at the University of Florida College of Medicine, which is supported in part by NIGMS P50 GM111152. This work was supported by Defense Advanced Research Projects Agency and the Army Research Office through Grant W911NF-15-1-0107. Ten_US
dc.format.extent694 - ?en_US
dc.languageengen_US
dc.language.isoenen_US
dc.relation.ispartofNat Communen_US
dc.rightsCreative Commons Attribution License
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectBiomarkersen_US
dc.subjectCommunity-Acquired Infectionsen_US
dc.subjectCross Infectionen_US
dc.subjectGene Expression Profilingen_US
dc.subjectHumansen_US
dc.subjectModels, Theoreticalen_US
dc.subjectPrognosisen_US
dc.subjectSepsisen_US
dc.subjectSeverity of Illness Indexen_US
dc.titleA community approach to mortality prediction in sepsis via gene expression analysis.en_US
dc.typeArticle
dc.rights.holderThe Author(s) 2018
dc.identifier.doi10.1038/s41467-018-03078-2en_US
pubs.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/29449546en_US
pubs.issue1en_US
pubs.notesNot knownen_US
pubs.publication-statusPublished onlineen_US
pubs.volume9en_US
dcterms.dateAccepted2018-01-18en_US
rioxxterms.funderDefault funderen_US
rioxxterms.identifier.projectDefault projecten_US


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Creative Commons Attribution License
Except where otherwise noted, this item's license is described as Creative Commons Attribution License